How Medical Device Companies Can Avoid Regulatory Delays in Germany

Most medical device companies assume the greatest challenge in Germany lies in meeting technical or clinical requirements. In reality, submissions are more often delayed by documentation than by science or technical shortcomings. A missing signature, inconsistent terminology, outdated supporting evidence, or a German translation for legal documents that does not reflect the original wording precisely can all delay the review process. These issues appear minor on paper, yet they can interrupt an otherwise well-prepared submission and extend market entry timelines. 

Why Submissions Take Longer Than Expected in Germany 

Germany's medical device market is estimated at approximately USD 43 billion, making it the largest in Europe. Medical devices under the EU MDR are primarily assessed by Notified Bodies, while BfArM, the Federal Institute for Drugs and Medical Devices, has responsibilities for clinical investigations, vigilance, and certain national regulatory functions. BfArM has improved its speed for simple, single-country clinical trials. Some now move in about a month. But that speed only applies when the documentation is accurate. The DMIDS portal used for applications rejects incomplete data. In 2024, it deletes draft applications left inactive for six months. That requirement alone has quietly resulted in delays for companies who planned to submit in stages.

The bigger issue runs deeper, though. Germany places equal emphasis on legal defensibility and technical accuracy. A risk assessment or clinical evaluation report is not just checked for science. It is checked as a record that must hold up if something goes wrong later. Companies coming from less stringent regulatory environments rarely understand this until after their first rejection.

The Mistakes That Keep Repeating

Companies that get stuck rarely get stuck on science. They get stuck on three avoidable problems. First, they treat translation as a last step. It is not. Technical files, instructions for use, and PRRC records all need German versions that match the source exactly. A translator with general medical knowledge but no MDR background may produce text that reads naturally yet fails regulatory review. Regulatory German has its own rules around liability wording, device classification terms, and warning language. These require subject-matter expertise rather than literal translation.

Second, companies underestimate how much Germany values consistency. Every document must remain consistent with all related submission materials. If a clinical evaluation report names a component one way, and the German file names it differently, reviewers flag it. The review timeline may be extended while the company explains the gap.

Third, companies assume one vendor can handle every document type the same way. Legal disclaimers, IFUs, labels, and clinical summaries carry different regulatory weight in Germany. Each needs a different specialist. Treating them as one batch of content to translate is how small errors slip through.

What Actually Works

Companies that move through BfArM smoothly share one common practice. They build translation into the regulatory timeline from day one. Moreover, they work with an ISO-certified translation service provider that has real MDR submission experience, not just general healthcare experience. Certification requires documented version control and accountability that informal translation work does not have.

These companies also take one simple step most others skip. A native German regulatory reviewer checks the final package before submission. This person checks for one thing specifically: terminology drift across documents. The review focuses on identifying terminology inconsistencies that could trigger regulatory questions.

They also plan around DMIDS directly. Knowing that inactive drafts get deleted after six months changes how work gets sequenced. They do not open an application until supporting documents, including the German versions, are close to final.

A Real Example Worth Learning From

B. Braun, a major German diagnostics and medical device manufacturer, offers a useful case study. The company has operated inside this regulatory system for decades. Internally, every translated regulatory document is managed as an independently controlled document. It is reviewed according to its own regulatory requirements, not simply checked against the English original. That separation matters. International companies entering the German market often skip this step in their first submission cycle. Skipping that review step often leads to repeated requests for clarification, extending market entry by weeks or even months. 

This approach extends beyond a single manufacturer. Smaller manufacturers who copy this approach report fewer review cycles. They also report fewer follow-up questions from BfArM. The reason is simple. Reviewers spend less time resolving inconsistencies. They spend more time on the actual submission. That shift alone can shorten a timeline by weeks.

Building the Habit Early

None of this requires a large team or a big budget. It requires a structured workflow. Identify which documents need German versions before drafting begins. Each document should be assigned to a translator with expertise in its regulatory function and given sufficient time for a native reviewer. Set this sequence early, and it becomes routine. Otherwise, each submission risks becoming a reactive exercise. 

The Real Lesson

Regulatory delays in Germany rarely stem from weak product design alone. More often, they arise from documentation that lacks consistency, traceability, or legal precision. Those are factors manufacturers can control through better planning.

Preparing regulatory documentation, technical files, and translations as one coordinated process reduces unnecessary review cycles and improves submission quality. Companies that treat every translated document as a regulated record are generally better positioned to navigate German regulatory requirements with fewer interruptions and greater confidence.